Professional Essentials · Free · No registration
Reactive arthritis
Recognize the inflammatory syndrome, address infection and choose treatment without overstating the evidence.
Reactive arthritis (ReA) is an inflammatory syndrome associated with a preceding infection, usually gastrointestinal or genitourinary. The central clinical task is to establish inflammation, judge whether the infection plausibly explains it, and identify problems requiring treatment now. An infection history provides context; it does not settle the differential diagnosis. The musculoskeletal illness and any persisting infection need coordinated but distinct treatment plans.
1. Recognize a pattern, not a mandatory triad
Asymmetric lower-limb oligoarthritis, heel enthesitis and dactylitis are characteristic presentations. Conjunctivitis or uveitis, mucocutaneous lesions and axial symptoms may accompany them. The historical arthritis–urethritis–conjunctivitis triad is not required. Chlamydial infection can be asymptomatic; patients of any sex may present without an obvious preceding genital illness.
Ask about diarrhea, sexual exposures, dysuria and treatment dates, alongside earlier episodes of back pain, psoriasis, nail disease, bowel inflammation and family history. Record the onset of infection and arthritis separately. ACR guidance emphasizes the infection-linked phenotype and variable course. HLA-B27 supports probability in context but neither confirms ReA nor predicts an individual outcome.
Reactive arthritis within the SpA spectrum → Open access
2. Resolve urgent alternatives first
A hot, rapidly swollen joint requires assessment for septic arthritis even after convincing enteritis. Arrange prompt aspiration when infection is suspected, sending fluid for culture, cell count and crystals. Neither absent fever, normal CRP, a negative Gram stain nor identified crystals safely excludes infection. Obtain blood cultures when bacteremia or sepsis is suspected. In a stable patient, sample before antibiotics; suspected sepsis requires immediate treatment without harmful delay. These principles follow the SANJO guideline.
Consider disseminated gonococcal infection with tenosynovitis, pustular lesions or septic oligoarthritis; genital symptoms may be absent. A painful red eye, photophobia or visual change requires same-day ophthalmic assessment. Lyme arthritis, crystal arthritis and emerging psoriatic or bowel-associated SpA require their own diagnostic pathways. Avoid intra-articular glucocorticoids while infection remains a serious possibility.
First-visit triage and differential diagnosis → Open access
3. Order tests that change a decision
There is no definitive ReA blood test. Use exposure-directed chlamydial and gonococcal NAAT, appropriate specimen sites and additional STI testing as indicated. An isolated antibody result does not establish current infection. Investigate ongoing significant diarrhea according to severity, epidemiology and immune status; a late negative stool test cannot exclude an already resolved trigger.
Blood count, renal and liver tests inform differential diagnosis and medication safety. CRP/ESR may help monitor a previously elevated signal, but normal values do not exclude localized inflammation. As outlined by NIAMS, examination, microbiology and selective imaging must be interpreted together. Ultrasound can locate fluid and guide aspiration. Persistent inflammatory back symptoms warrant an axial assessment; an isolated imaging abnormality does not establish its cause. Assign responsibility for every pending result.
Testing and specimen selection → Professional access required
4. Treat infection for its own indication
Treat an active STI even when the arthritis is improving. For uncomplicated chlamydial infection in nonpregnant adolescents and adults, CDC recommends doxycycline 100 mg twice daily for seven days; pregnancy and complications require separate regimens. Address partners, prevention of transmission and reinfection testing. Routine test of cure is usually unnecessary in nonpregnant patients after appropriate treatment; NAAT before four weeks can detect nonviable organisms. Retesting around three months addresses reinfection.
Persistent joint symptoms alone do not justify extending antibiotics. NICE advises against courses of four weeks or longer solely for ReA after the initial infection is treated. A 42-patient randomized trial favored six-month combination therapy in selected chronic chlamydial disease with research PCR positivity. That specialized selection is not interchangeable with a positive genital NAAT and does not establish routine treatment for postenteric or unselected ReA.
What the prolonged-antibiotic trial establishes → Professional access required
5. Control inflammation while restoring movement
An NSAID is a usual initial option when kidney, gastrointestinal, cardiovascular and reproductive risks permit. Check dehydration after diarrhea, interacting medicines and duplicate nonprescription NSAIDs. Use one agent with a defined review of benefit and adverse effects. Persistent monoarthritis or oligoarthritis may respond to local glucocorticoid after infection is excluded. Severe polyarticular disease can justify a short systemic course with a planned endpoint.
Medication and rehabilitation should proceed together. Protect a very painful joint temporarily, then restore range of motion, strength and tolerable activity. Adjust tendon loading, footwear and work demands. Repeated steroid courses or continued disabling synovitis should trigger reassessment and a steroid-sparing discussion; clinicians need not wait for an arbitrary six-month threshold. Residual mechanical pain, weakness or sleep disruption deserves treatment without automatically increasing immunosuppression.
6. Escalate with an explicit evidence discussion
Sulfasalazine has direct but mixed randomized evidence: the Clegg trial showed a treatment signal, while Egsmose and colleagues found no significant six-month between-group difference in intention-to-treat analyses. Methotrexate is used for persistent peripheral disease, with less direct ReA trial evidence. Prescribing requires drug-specific monitoring, reproductive planning and, for methotrexate, clear once-weekly dosing.
TNF inhibitors are a clinical option for severe or persistent active ReA inadequately controlled by conventional treatment. The Icelandic observational cohort reported improvement, but controlled comparative evidence remains limited. This uncertainty does not establish ineffectiveness. Treatment for ReA may be off-label; document selection, infection screening, expected outcomes and review timing. A 2025 tofacitinib comparison was small and nonrandomized, not proof of equivalence or long-term safety. JAK cardiovascular, malignancy and thrombotic warnings remain relevant.
Refractory disease and targeted therapy → Professional access required
7. Reassess the diagnosis as well as the treatment
Follow swollen joints, entheses, function, medication burden and adverse effects. Ask again about eyes, bowel symptoms, psoriasis and sustained axial symptoms. Many episodes improve over months, but persistent or recurrent inflammation may require long-term treatment or a revised SpA diagnosis. New fever or a new hot joint reopens the infection question.
Agree on a concrete functional goal and a review date. In stable remission, consider treatment reduction with a recurrence plan; no single ReA-specific taper suits everyone. Pregnancy, immunocompromise, childhood disease and symptoms after intravesical BCG require additional condition-specific assessment. Keep the infection follow-up and the arthritis follow-up clearly assigned.
A useful review distinguishes three situations: less inflammation with a lower treatment burden; persistent inflammation despite adequate exposure; and continuing pain after swelling has settled. The first supports recovery, the second prompts diagnostic and therapeutic reassessment, and the third calls for examination of residual tendon disease, stiffness, conditioning and other pain mechanisms. These are clinical reasoning categories, not a validated ReA response score.
Before declaring a drug ineffective, establish the dose actually taken, duration, interruptions and tolerability. Improvement obtained only with repeated rescue steroids differs from sustained control. If another SpA phenotype becomes better supported, explain the revised diagnosis and use its treatment evidence explicitly. Conversely, a response to a biologic does not prove which infection triggered the original episode. Record uncertainty in the assessment while still making a practical plan for the next visit.
Longitudinal reassessment → Professional access required
Sources and further reading
- American College of Rheumatology. Reactive arthritis. Updated February 2025.
- NIAMS. Reactive arthritis: diagnosis, treatment and steps to take. Reviewed May 2024.
- Ravn C et al. SANJO guideline. J Bone Jt Infect. 2023;8:29–37.
- CDC. Chlamydial infections. Gonococcal infections, including disseminated infection.
- NICE NG65. Spondyloarthritis: recommendations, including reactive arthritis.
- Carter JD et al. Combination antibiotics for chronic Chlamydia-induced reactive arthritis. Arthritis Rheum. 2010;62:1298–1307.
- Clegg DO et al. Sulfasalazine versus placebo. Arthritis Rheum. 1996;39:2021–2027. Egsmose C et al. Ann Rheum Dis. 1997;56:32–36.
- Thorsteinsson B et al. TNF inhibitors in reactive arthritis: Icelandic cohort. J Rheumatol. 2020;47:1575–1581.
- Mruthyunjaya P et al. Sulfasalazine and tofacitinib: observational comparison. Int J Rheum Dis. 2025;28:e70370.
- FDA. Safety warnings for selected JAK inhibitors.